Interleukin 6 is a 184-aa polypeptide postulated to belong to the class of helical cytokines. We built a three-dimensional model of human interleukin 6 based on the similarity of its hydrophobicity pattern with that of other cytokines and on the x-ray structure of growth hormone, interleukin 2, interleukin 4, interferon P,. and granulocytemacrophage colony-stimulating factor. The resulting model is a bundle of four a-helices and suggests possible alternative conformations for the 9 C-terminal amino acids; in this region,
macrophage colony-stimulating factor. The resulting model is a bundle of four a-helices and suggests possible alternative conformations for the 9 C-terminal amino acids; in this region, the importance of Arg-182 and Met-184 for biological activity has been demonstrated [Lutticken, C., Kruttgen, A., Moller, C., Heinrich, P. C. & Rose-John, S. (1991) FEBS Lett. 282, 265-267]. Therefore, we generated a large collection of singleamino acid variants in residues 175-181. Analysis of their biological activity in two systems and the receptor binding properties of a subset of the mutants indicates that the entire region is involved in forming the receptor binding surface and supports the hypothesis that this region does not assume an a-helical conformation. Remarkably, we also found a mutant with receptor affinity and biological activity much higher than wild type; the potential therapeutical value of this fiding is discussed.
Interleukin (IL) 6 is a multifunctional cytokine produced by a variety of cell types that acts as a differentiation and growth factor for cells of the immune system, hepatocytes, kidney mesangial cells, hematopoietic stem cells, keratinocytes, and neurons (1, 2) . Some aspects of the interaction of IL-6 with target cells have been elucidated through the cloning of two transmembrane molecules that constitute the IL-6 receptor system: the low-affinity 80-kDa IL-6 receptor (3) and the signal transducer protein gpl3O (4) . However, the features of the interaction between these molecules have remained largely unknown, due to lack of information about their three-dimensional structure and #of systematic site-directed mutagenesis. After the x-ray structure of porcine growth hormone (pGH) had been determined (5), Bazan (6) carefully analyzed the hydrophobicity patterns of several cytokines including IL-6 binding to class I receptors. He predicted that these molecules form an antiparallel four-helix bundle, with the same connectivity observed in pGH. The general folding topology of an antiparallel four-helix bundle has been proven to be shared by all helical cytokines for which x-ray or NMR structures have been determined (7) (8) (9) (10) (11) , although significant local differences can be observed, hinting at the possible existence of structural subclasses.
To assess the compatibility of human (h) IL-6 with this folding pattern, we have built a three-dimensional model of hIL-6 that shows that the predicted topology can be assumed by the hIL-6 sequence with reasonably good internal packing and agreement with the available experimental data. The helix boundaries in our model do not precisely match those previously predicted. More importantly, it is possible that the functionally essential C-terminal region of the molecule, proposed as being included in helix D (6, 12) , assumes a nonrepetitive structure similar to that observed in human granulocyte-macrophage colony-stimulating factor (hGM-CSF) (8) . To test this possibility, we performed saturation mutagenesis on this region of the molecule and tested the mutants in two biological assays on murine and human cells. Our data show that residues located in the C-terminal region, in addition to those previously identified, are involved in IL-6 receptor binding and are consistent with these residues being in a nonhelical conformation.
MATERIALS AND METHODS
Sequences used are from Releases 21.0 and 31.0 of the Swiss-Prot and EMBL (pIL-6) sequence data bases, respectively. Data bank codes are as follows: hIL-6, IL6 HUMAN; murine (m) IL-6, IL6_MOUSE; rat (r) IL-6, IL6_RAT; pIL-6, SSPRO; human granulocyte (hG) CSF, CSF3-HUMAN; mG-CSF, CSF3_MOUSE; chicken myelomonocytic growth factor, MGF CHICK. The numbering used for the hIL-6 sequence is shown in Fig. 1 . For the multiple sequence alignment, the program PILEUP in the GCG package was used with default parameters (13) . The coordinates of hGM-CSF (8) and interferon p3(7) are prerelease entries 1GMF and 1IFA ofthe Brookhaven Protein Data Bank (14) . Models were built using the program INSIGHT (15) .
Generation of Substitution Mutants. The generation of substitution mutants in positions 177, 178, and 179 has been described (16) . Mutants in positions 175, 176, 180, and 181 were generated using the same PCR strategy illustrated in figure 1 of Fontaine et al. (16) . Some of the mutant cDNAs were also subcloned into Escherichia coli expression vector pT7.7 (17) .
Expression of Mutant Proteins, Bioassays, and in Vitro Binding Assays. Mutant proteins were expressed, as described, either by production in E. coli (18, 19) Only the mature peptides (as stated in the corresponding data base entry) are shown (for pIL-6, the length of the mature peptide was decided by homology to the other IL-6 sequences). The conserved hydrophobic pattern indicated by boxed residues predicts four helices (A, B, C, and D) represented by open bars. The dashed part of helix D corresponds to the last 9 C-terminal residues for which an alternative conformation is possible. Shaded bars indicate the secondary structure assignment according to Bazan (12) . cMGF, chicken myelomonocytic growth factor. amount of the various mutants necessary to give halfmaximal stimulation in each assay. In vitro binding assays and competition experiments were performed as described by Fiorillo et al. (19) .
RESULTS
Model Building. Fig. 1 shows a multiple alignment of hIL-6 with the only other cytokine sequences in the sequence data bases showing significant amino acid similarity (17% or more identical residues) over the entire length of the mature polypeptide. From the conserved hydrophobicity pattern indicated in the figure, we derived a secondary structure assignment consisting of four helices, as predicted by Bazan (6, 12) , but with some differences in their boundaries and lengths. To select the most likely orientation of the four helices in the bundle, we obtained the best superposition of the helix axes of the two available structures (Protein Data Bank entries, 1GMF and 1IFA). The superposition was used as a guideline throughout the modeling. Intermediate values of interhelix angles between the two structures were taken as a tentative starting point. The sequence was threaded through the helices, selecting the register that gave the best internal hydrophobic packing. Both the interhelix angles and the side-chain conformations (initially set to the most frequent rotamers) were subsequently manually optimized and subjected to a limited energy refinement (15) (Tables 1 and 2 ). The solvent-accessible surface of the final model did not reveal any sizeable internal cavity.
Due to the lack of both experimental data and significant sequence similarity to the helical cytokines of known structures, we could not reliably model the long loops A-B and C-D connecting the hIL-6 helices (Fig. 2) . However, the presence of two disulfide bridges in hIL-6, between Cys-45 and Cys-51 and between Cys-74 and Cys-84 (23), allowed us to tentatively position the first 5 and the last 9 residues of the A-B loop. The predicted length of the hIL-6 A-B loop is -10 aa longer than the equivalent regions in hGM-CSF, hIL-4, or hIL-2, where the A-B and C-D loops pack compactly, forming a small /3-sheet, whereas in pGH, hGH, and inter- Bazan (12) proposed that helix D extends up to the C terminus of IL-6 and that a major receptor-binding determinant (called the D2 motif) is situated in the middle of helix D. The structure of the recently determined complex between hGH and its receptor (extracellular domain of the hGH receptor) shows that in this molecule the receptor-binding site extends from the D2 motif toward the N-terminal part of helix D (9) . In contrast, in hIL-6, residues C-terminal to the D2 motif are known to be important determinants in receptor binding (24) . Therefore, a different conformation for the C-terminal region of IL-6 cannot be excluded. Our model does not allow us to discriminate between the two alternative conformations schematically shown in Fig. 2 . This question was, therefore, addressed through site-directed mutagenesis.
Saturation Mutagenesis of the hIL-6 C Terminus. To gain insight about both the structure and function of the hIL-6 C-terminal region, we generated a series of single-amino acid substitutions in this region. We focused our attention on residues 175-181, Gln-Ser-Ser-Leu-Arg-Ala-Leu. The last 3 aa Arg-182, Gln-183, and Met-184 have been mutated by others (24, 25) .
Mutants were generated at the cDNA level by PCR and sequenced over the entire PCR-amplified region. For analysis of biological activity, we selected 45 variants, of which 3 unexpectedly had 2-aa substitutions instead of 1: 169Asn/ 177Val, 105Ile/18OThr, and 108Asn/181Cys (see Fig. 3 ). For each position, 5-8 mutants were examined for their biological activity to identify the features necessary for proper functioning.
Biological Activity of hIL-6 Mutants. Wild-type and mutant hIL-6 molecules were obtained by in vitro transcriptiontranslation and the biological activities of the mutants were determined in two assays on cells of human and murine origin. hIL-6 activity on human cells was measured by its ability to enhance transcription from acute-phase gene pro- moters in cells of hepatic origin (26) ; therefore, mutants were tested for their ability to induce chloramphenicol acetyltransferase (CAT) activity from a human C-reactive protein promoter-CAT fusion transfected into the human hepatoma cell line Hep 3B (19) . The results obtained in this system are particularly relevant because they depend on the efficient interaction of the cytokine with the homologous receptor system. Mutants were also tested in the classical hybridoma growth factor assay for their ability to stimulate growth of the hIL-6-dependent murine hybridoma cell line 7TD1 (22) . The results are shown in Fig. 3 . For mutants of Ser-177, Leu-178, and Arg-179, the activity on mouse cells has been described (16) and is reported here to facilitate the comparison of their activity in the two systems.
Gln-175 can be replaced with several other residues (with the exception of Asp) without drastic effects (residual activity, >30%) on mouse cells. On the contrary, small side chains (Gly, Ala, and Asn) are not well-tolerated in human cells (Fig.  3) . All mutations of Ser-176 have no detrimental effect. The substitution Serl76Arg is the only one found to be significantly more active than wt hIL-6 (370 ± 90%) on human cells. The most active protein on mouse cells is Serl76Val (480 ± 10% compared to wt hIL-6). Interestingly, Val is the amino acid found in the corresponding position in mIL-6 ( Fig. 1) and the mutant behaves exactly like mIL-6, which shows a specific activity roughly 5-fold higher than hIL-6 on murine cells (19) . Serl76Pro shows almost full activity when tested on human cells (73 ± 17%) and even higher levels of activity than wt hIL-6 when tested on mouse cells (150 ± 48%). The activity of mutants with substitutions in position 177 and 178 on mouse cells has been described (22) and is included in Fig.  3 . Surprisingly, the behavior of these mutants is quite different when they are tested on human cells. At position 177 Serl77Val/Serl69Asn, Alal8OThr/PhelOSIle, and Leul81Cys/ SerlO8Asn are underlined. Symbols in parentheses after the residue type refer to the predicted degree ofaccessibility according to models A and B, respectively. b, Buried; h, half-buried; e, exposed. the analyzed region always causes a significant drop of biological activity in both cell lines (Fig. 3). (ii) With only two exceptions (Glnl75Leu and Serl76Arg), the effects of the mutations are more detrimental when the mutants are tested on human cells than on mouse cells. This effect has been observed before (19, 23) and may be attributable to a different degree of tolerance of the murine vs. the human receptor complex. It is well-established that although the mouse 80-kDa receptor efficiently binds hIL-6 and mIL-6, the human receptor recognizes only the human cytokine (19) . (iii) Single Pro substitutions at any of six of the seven positions are sometimes compatible with residual biological activity (as shown by the behavior of Serl76Pro and Alal8OPro), not to be expected if the region is folded as an a-helix (see Discussion Affinity for the soluble hIL-6 receptor of mutant hIL-6 produced in E. coli compared to the observed biological activity.
introduced (to minimize variations due to the type of substitution made), (ii) produce contrasting behaviors in human cells, and (iii) have preserved their activity on mouse cells, a strong indication that their conformation is not grossly altered. Therefore, we selected Serl76Arg, the only mutant with higher biological activity in human cells, and Alal80Arg, which is totally inactive. The cDNAs coding for these two variants were transferred in the E. coli expression vector pT7.7 (17) and large amounts of the two proteins were produced and purified to homogeneity (19) . They showed biological activity identical to that obtained with the in vitro-synthesized proteins ( Table 3 ). The binding of the mutant proteins to the recombinant soluble hIL-6 receptor was calculated as the ratio between the amount of unlabeled wt hIL-6 and mutant protein necessary to displace 50%o of receptor-bound wt 1251-labeled hIL-6. The results (Table 3) show that there is agreement between biological activity of the mutant on human Hep 3B cells and their affinity for the soluble hIL-6 receptor.
DISCUSSION
Our present knowledge of structure-function relationships in the large group of molecules known as helical cytokines emphasizes the importance of the C-terminal region for receptor binding and biological activity (27) (28) (29) (30) . This has also been demonstrated for hIL-6, by immunological evidence [binding of neutralizing monoclonal antibodies (31) ] and by limited site-directed mutagenesis (24) . Our three-dimensional model of hIL-6 shows that this important region of the molecule can have one of two alternative conformations: either the terminal helix D extends to (or close to) the very end of the chain, as seen in pGH, hGH, hIL4, or hIL-2 (5, 7, 9-11), or helix D is one or two turns shorter as in hGM-CSF (8) and the last part of the chain adopts a nonhelical conformation. In the absence of x-ray crystallographic or NMR studies, our saturation mutagenesis approach was directed to select one of these two possibilities.
Our data, besides showing that the C-terminal region carries several determinants of receptor binding, either through direct contacts or by stabilizing the local structure of the cytokine, strongly favor the alternative that the last 9 residues (aa 176-184) are not folded as a continuous a-helix.
This conclusion is based on the following evidence:
(i) Serl76Pro has normal or even higher than wt activity in human and murine cells, respectively. Moreover, the mutant protein can be immunoprecipitated as well as wt hIL-6 by MabBl (data not shown), which recognizes a discontinuous epitope formed by amino acids Pro-18 to Asp-26 in the N terminus and Leu-181 to Met-184 at the C terminus (31) . Therefore, from all the data available so far, this mutation does not seem to alter or change the relative positioning ofthe N and C termini, an observation that is hardly compatible with residue 176 being in a canonical helical environment. a-Helices containing prolines, in general, show kinks (32) . For hIL-6, even a small kink would significantly alter the local structure around Pro-176 and affect receptor binding and possibly recognition by the conformational MabBl (31) .
(ii) Our previous mutagenesis studies showed that Arg-179 is on the hIL-6 surface and is involved in receptor binding (16) . The results presented here indicate that the adjacent residues Ser-176, Ser-177, Leu-178, Ala-180, and Leu-181 are also exposed and face the receptor binding surface. The behavior of mutants such as Serl77lle, Leul78Tyr , and Alal80Arg, which are not active at all in human cells but correctly folded as indicated by their normal or moderately reduced activity in the murine system, can most easily be explained by these residues being at least partially exposed on the cytokine-receptor interface. Only very conservative substitutions (from the sterical point of view) in positions 178 (Leul78Thr) and 180 (Alal8SSer) maintain activity in human cells, suggesting that residues Leu-178 and Ala-180 play an active role with Arg-179 in binding the hIL-6 receptor. Finally, Ser-176 and Leu-181 are also located on the cytokine-receptor interface, even ifthey are not likely to be direct contact points in the human system because of the high number of substitutions that maintain activity in human cells. This is suggested by the behavior of mutants Serl76Val and, to a lesser extent, Leul81Thr: in both cases restoring the murine sequence in the respective positions causes a specific increase in activity in mouse cells. All these data favor our model B (the nonhelical conformation), which also better fits the mutation data with respect to the predicted accessibility of the individual residues (Fig. 3) .
While this report was in preparation, Leebeek et al. (33) described a set of mutants on the hIL-6 15 terminal amino acids, in which one, two, or at most three substitutions per each position were generated and analyzed using similar assay conditions. The data on the biological activity of their mutants are compatible with our model. In particular, they also find that the Serl76Pro mutant (Serl77Pro in their numbering) is fully active, contrary to previous reports by others (24) . In addition, their data confine the receptor binding site to residues C-terminal to Gln-175.
In our collection of 45 hIL-6 mutants, we also find a strong up mutant (Serl76Arg, 3-to 4-fold higher activity on human cells). Receptor binding studies with this mutant confirm that increased activity is due to increased receptor affinity. This result, while strengthening the hypothesis that Ser-176 is on the cytokine-receptor interface, is of practical interest, given the potential of using hIL-6 in the therapy of neoplastic diseases and thrombocytopenia (34) . The clinical use of receptor super binders, such as our Serl76Arg, therefore, could allow a decrease in the dosage ofcytokine administered to the patient.
Our model has been helpful in designing the mutants described in this report that allowed us to choose between two possible conformations for the C-terminal part of the molecule. We intend to follow a similar strategy to solve the ambiguities that still remain about the A-B and C-D loops and to extend the mapping of the binding site to other parts ofthe hIL-6 molecule to obtain a more complete picture ofthe interactions with the hIL-6 receptor. The results from homolog scanning mutagenesis (19) indicate that there are also receptor binding determinants in the region of residues 28- 92, which, in our model, is located in the end part of the A-B loop. In hGH, hIL-2, and hGM-CSF, the end part ofthe A-B loop is indeed part of the receptor binding site (9, 27, 35 (14) . This suggests that surface complementarity, rather than charge complementarity, is the predominant mode of recognition and demonstrates that, even with the knowledge of the detailed three-dimensional structure of one cytokine-receptor complex, to predict those contacts for other cytokine-receptor systems will not be a trivial problem.
